

**A COMPREHENSIVE REVIEW ON HYPERTENSION:
PATHOPHYSIOLOGY DIAGNOSIS MANAGEMENT****Miss. Supriya Bansode*, Mr. Shreyash Bawge, Miss Nikita Achintalwar**B. Pharmacy Final Year Student, Kalandi Ta. Nilanga, Dist. Latur, Nilanga, Maharashtra,
India.Article Received on 05 Feb. 2026,
Article Revised on 25 Feb. 2026,
Article Published on 01 March 2026<https://doi.org/10.5281/zenodo.18884063>***Corresponding Author****Miss. Supriya Bansode**B. Pharmacy Final Year Student,
Kalandi Ta., Nilanga Dist. Latur,
Nilanga, Maharashtra, India.**How to cite this Article:** Miss. Supriya Bansode*, Mr. Shreyash Bawge, Miss Nikita Achintalwar. (2026). A Comprehensive Review on Hypertension: Pathophysiology Diagnosis Management. World Journal of Pharmaceutical Research, 15(5), 1413-1434.

This work is licensed under Creative Commons Attribution 4.0 International license.

1. ABSTRACT

Systemic arterial hypertension is considered the leading adjustable risk factor contributing to global illness and death, especially because of its strong link to cardiovascular diseases (CVD). A large portion of individuals living with hypertension remain undiagnosed, and many who are diagnosed either do not receive treatment or are not adequately managed. Effective control of blood pressure significantly lowers the worldwide burden of disease and reduces mortality rates. The development of hypertension results from a multifactorial interaction between environmental influences, genetic susceptibility, and various pathophysiological mechanisms involving multiple organs and systems. Proper clinical evaluation of a hypertensive patient requires accurate and standardized blood pressure measurement, assessment of the patient's estimated risk for atherosclerotic cardiovascular disease, screening for

target organ damage, identification of possible secondary hypertension, and evaluation of associated conditions such as cardiovascular and kidney disorders. Adopting lifestyle modifications, such as healthy dietary habits and regular physical activity, plays a crucial role in reducing blood pressure and preventing the onset of hypertension and its cardiovascular complications. Drug therapy is also highly effective in controlling blood pressure and decreasing the risk of CVD in most patients. Commonly recommended first-line antihypertensive drugs include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, dihydropyridine calcium channel blockers, and thiazide diuretics.

KEYWORD: Target Blood Pressure; Antihypertensive Drugs Therapy, Renal Denervation; Systemic Arterial hypertension renin-angiotensin-aldosterone system.

2. INTRODUCTION

Hypertension, defined as an increase in systolic blood pressure, blood pressure, or both above normal ranges, is widespread in both industrialized and developing countries, and its prevalence rises with age. Systemic arterial hypertension also known as hypertension is defined by persistently high blood pressure (BP) in the systemic arteries. The ratio of systolic BP the pressure that the blood exerts on the artery walls when the heart contracts to diastolic BP the pressure when the heart relaxes is widely used to express blood Pressure.




Fig. No.1: Hypertension.

High blood pressure, commonly referred to as hypertension, is a serious health condition that greatly increases the likelihood of developing heart disease, stroke, and can even lead to premature death. Blood pressure represents the force exerted by circulating blood against the arterial walls. This pressure is influenced by vascular resistance and the amount of effort required by the heart to pump blood throughout the body.

A combination of genetic susceptibility and poor lifestyle habits contributes to the development of hypertension. Lack of physical activity, unhealthy diet, smoking, excessive alcohol consumption, and obesity are major environmental triggers. Because many of these factors can be modified, hypertension is considered one of the most preventable causes of illness and death. Maintaining a healthy lifestyle through regular exercise and a well-

balanced diet plays a crucial role in lowering blood pressure and preventing complications. The central aim of treatment is to minimize risk factors associated with hypertension while maintaining the patient's quality of life.

Previously, hypertension was generally diagnosed when blood pressure consistently exceeded 140/90 mmHg. However, the 2017 guidelines by the American College of Cardiology and the American Heart Association (ACC/AHA) introduced stricter criteria, defining hypertension as systolic pressure of 130 mmHg or greater or diastolic pressure of 80 mmHg or greater.^[1]

Under the older definition, the prevalence of hypertension among adults in the United States was 31.9%. According to the updated 2017 guidelines, this prevalence increased to 45.6%.^[2] Among treated individuals, control of hypertension dropped from 61.0% (target <140/90 mmHg) to 46.6% when the lower target of <130/80 mmHg was applied.^[2] Use of appropriate antihypertensive medications not only reduces blood pressure but also helps prevent target organ damage, thereby significantly decreasing the risks associated with elevated BP.

Blood Pressure Ranges

Blood Pressure Ranges		
BLOOD PRESSURE CATEGORY	SYSTOLIC (mm Hg)	DIASTOLIC (mm Hg)
Healthy	less than 120	and less than 80
Elevated	120–129	and less than 80
Stage 1 hypertension	130–139	or 80–89
Stage 2 hypertension	140 or higher	or 90 or higher
Hypertension crisis	over 180	or over 120

healthline

Fig.No.2 Blood Pressure Ranges.

1.1 SPHYGMOMANOMETER

A mercury sphygmomanometer is the common device used to monitor blood pressure. Mercury, which has long filled the middle column of traditional sphygmomanometers, is measured in unit mercury.




Fig.No. 3: Sphygmomanometers.

A sphygmomanometer is used in hypertension because it is the instrument that measures blood pressure, which is essential for diagnosing, monitoring, and managing hypertension.

To measure blood pressure accurately

Hypertension means high blood pressure, so the only way to identify it is by measuring BP using a sphygmomanometer.

1. To detect hypertension early

Regular BP checks help detect high blood pressure even when no symptoms are present

2. To monitor treatment effectiveness

Patients on antihypertensive medicines need BP measurement to see whether treatment is working

To prevent complications

Uncontrolled hypertension can cause

Heart attack

Stroke

Kidney failure

Vision problems

Types of sphygmomanometers

1. Mercury sphygmomanometer
2. Aneroid sphygmomanometer
3. Digital BP monitor

3. Literature Review

3.1 Sneha Rawat¹, Praveen Kumar Ashok², Reetu Papola³(2023)

Hypertension is a significant global health concern, and its prevalence is increasing due to the aging population. Preventive strategies, such as maintaining a healthy diet and engaging in regular physical activity, should be implemented early in life to reduce the risk of developing hypertension. Effective management of hypertension often requires the use of combination therapy, as single medications may not provide adequate blood pressure control for many patients. The selection of drug combinations should be rational and evidence-based, taking into account the patient's overall health, coexisting conditions, and the pharmacological properties of the medications. This individualized approach ensures optimal blood pressure control, minimizes adverse effects, and improves long-term health outcomes.

3.2 Samaneh Gooranil, *Somaye Zangene² And John D. Imig¹,*(2024)

Hypertension has a staggering economic burden on governments. Its annual costs are estimated at USD 79 billion in the United States alone Hypertension and co-morbidities, such as diabetes, also need further investigation. Treatment and control of these conditions require screening, patient education, and health centers. Continued research on hypertension and investment in its management and related diseases is vital. By expanding our understanding of the underlying mechanisms, improving access to effective interventions, and taking advantage of technological advances, researchers and healthcare providers can work towards reducing the devastating impact of this condition

3.3 Katarzyna Sawicka^{1,2}, Michal Szczyrek¹, Iwona Jastrzębska¹, Marek Prasa², Agnieszka Zwolak¹, Jadwiga Daniluk¹.(2011)

Elevated arterial pressure is the most important public health problem in developed countries being common, asymptomatic, readily detectable, usually easily treatable, and often leading to lethal complications if left untreated. Effective hypertension treatment can reduce the risk of Stroke, heart attack and congestive heart failure, hypertensive retinopathy and

nephropathy. The goal of hypertension treatment is to reduce blood pressure levels. Treatment of hypertension and proper lifestyle changes reduce the risk of serious hypertension complications.

3.4 Arshad Muhammad Iqbal; Syed F. Jamal(2023)

In the case of resistant hypertension, a multi-disciplinary approach merits consideration. A cardiologist, nephrologist, and hypertension specialist should manage such patients in consort. Often patients will also require psycho-social counseling and consultation with nutritionists and dieticians.

3.5 Jun Ma, Xiaoping Chen (2022)

Hypertension is a disease named after its clinical features, which is doomed to the diversity of its pathogenesis. Unlike secondary hypertension with determined causes, the underlying mechanisms of essential hypertension have not been fully elucidated yet. The complicated mechanisms and poor understanding make it difficult to cure essential hypertension. Continued in-depth mechanism study, especially the application of cutting-edge theories to the pathogenesis of hypertension, will be of great help in overcoming existing difficulties. On the other hand, optimizing the existing antihypertensive methods with blood pressure as the core goal is an important research direction for the clinical treatment of hypertension.

3.6 T. Anantha lakshmi, M. Ramesh, B. Mounika, K. Bhuvanewari, Sreekanth Nama(2013)

Hypertension is prevalent worldwide and aging of the population means that there are more and more people with hypertension. Therefore, the scale of the problem of diagnosing, treating and controlling hypertension is immense. Current efforts are channeled towards the detection and treatment of hypertension in middle and old age. The linear rise in the prevalence of hypertension with age means that measures to prevent hypertension, such as a healthy diet and regular physical activity, should start early in life. For those who have already developed hypertension, early diagnosis and treatment is important. Existing antihypertensive drugs are not ideal individually and so a combination of drugs is needed in a large proportion of patients. The choice of such drugs should be rational and evidence-based.

3.7 Dr.Arun Patel Atul Kumar Barman, Ankit Gupta (2021)

As reviewed by Dr. Arun Patel, Atul Kumar Barman, and Ankit Gupta, hypertension continues to be one of the most significant contributors to global morbidity and mortality. Its complex origin, involving cardiovascular, renal, neuroendocrine, and metabolic pathways,

highlights the need for a multidimensional approach to prevention and management. Improved diagnostic strategies, including ambulatory and home blood pressure monitoring, along with individualized treatment based on risk stratification, have strengthened current clinical practices. A combination of healthy lifestyle interventions and evidence-based pharmacotherapy remains the most effective strategy for achieving optimal blood pressure control. Strengthening patient awareness, enhancing clinical follow-up, and advancing research on newer therapeutic targets are crucial for reducing long-term complications. With collective efforts in healthcare, public policy, and patient education, the overall burden of hypertension can be significantly reduced.

4. Mechanisms/Pathophysiology

Hypertension is a long-standing rise in arterial blood pressure that progressively leads to damage in vital organs and is associated with higher morbidity and mortality. Blood pressure depends on both cardiac output and systemic vascular resistance. Vascular resistance may increase due to heightened stimulation of α -adrenergic receptors or excessive production of vasoactive peptides such as angiotensin and endothelins. These mechanisms raise intracellular calcium levels in vascular smooth muscle cells, resulting in vasoconstriction.

In addition to vasoconstriction, peptides like angiotensin and endothelins act as growth promoters, contributing to vascular smooth muscle hypertrophy and remodeling. With advancing age, loss of elasticity and stiffening of the aorta and major arteries widen pulse pressure. The autonomic nervous system also significantly influences blood pressure regulation. Individuals with hypertension often exhibit increased secretion of norepinephrine and greater peripheral responsiveness to it, along with exaggerated reactions to stress.

Another characteristic finding in hypertension is altered baroreflex control, including a shift in the baroreceptor set point and reduced sensitivity. The renin-angiotensin-aldosterone system (RAAS) is particularly important in some types of hypertension, such as renovascular hypertension, whereas it is suppressed in conditions like primary hyperaldosteronism. Elderly people and individuals of African descent frequently present with low-renin hypertension.

4.1 Blood Pressure Regulation

Blood pressure is regulated by several cardiovascular factors, such as total blood volume, cardiac output (the amount of blood ejected by the heart per minute), and arterial tone. Arterial tone is largely influenced by intravascular volume and a network of neurohumoral

mechanisms. Normal BP control depends on the coordinated actions of multiple regulatory systems, including the renin-angiotensin-aldosterone system (RAAS), endothelial-derived factors and natriuretic peptides, the sympathetic nervous system (SNS), and immune-mediated processes. Any abnormality or dysfunction in these regulatory components can alter BP, either directly or indirectly.

The maintenance of normal physiological blood pressure requires an integrated response from several organ systems. Blood pressure is primarily determined by

- Cardiac Output: the volume of blood pumped by the heart each minute
- Blood Volume: the total volume of circulating blood.
- Arterial Tone: influenced by intravascular volume and neurohumoral regulation.

These mechanisms are governed by a complex neurohumoral network involving RAAS, natriuretic peptides, vascular endothelium, the SNS, and immune pathways. Disturbances in any of these regulatory systems may raise mean BP or increase BP variability. Persistent dysfunction can eventually result in damage to target organs, such as the heart (left ventricular hypertrophy) and kidneys (chronic kidney disease), leading to serious cardiovascular consequence.

The underlying pathophysiology of hypertension is multifactorial and strongly influenced by genetic susceptibility. Primary hypertension is attributed to the interaction of several genes, with specific genetic variants being associated with a higher likelihood of developing the condition. These gene variations are commonly linked to a positive family history. In addition to this inherited predisposition, various environmental and lifestyle factors such as excessive sodium consumption, poor sleep quality or sleep apnoea, high levels of psychological stress, and excessive alcohol use contribute significantly to elevated blood pressure.

Advancing age further increases the risk of hypertension due to gradual stiffening of arterial walls, which results from progressive changes in vascular collagen and increased development of atherosclerosis. Immune-mediated mechanisms are also implicated, particularly in individuals with chronic infections or autoimmune disorders such as rheumatoid arthritis. The mosaic theory of hypertension highlights this multifaceted interplay of genetic, environmental, vascular, and immunological factors in the development of high blood pressure.




Fig. No.: 4 BP Regulation.

5. DIAGNOSIS

Since essential or primary hypertension frequently has no symptoms, all individuals should have their blood pressure checked at routine doctor appointments. Because essential or primary hypertension usually does not present with noticeable symptoms, it is recommended that every individual undergo regular blood pressure evaluation during routine medical check-ups. The diagnosis of hypertension is most commonly made through repeated BP measurements obtained in a clinical setting. Accurate measurement and proper documentation are essential for identifying the degree of blood pressure elevation, estimating cardiovascular disease (CVD) risk, and determining an appropriate treatment plan.

Since 2010, there has been a growing use of methods for measuring blood pressure outside the clinical environment to assist in both diagnosis and management. These methods include ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM), which provide reliable and comprehensive readings.

Diagnosis of elevated BP alone is insufficient when evaluating a person with hypertension. Proper assessment should also include screening for secondary causes, evaluating CVD risk, identifying target organ damage, and recognizing other health conditions that may influence BP or worsen complications. These evaluations consist of both routine investigations and specialized assessments. In rare hereditary cases, a single gene mutation may be responsible

for hypertension, and identifying such cases may lead to complete cure or remarkable improvement in BP management, along with reduced CVD risk.

Therefore, a basic screening for secondary hypertension is advisable for all patients, which should include clinical history-taking, physical examination, and appropriate laboratory tests. Management and treatment: Lifestyle modification remains the first and most effective approach for controlling hypertension

Hypertension is confirmed when a person consistently shows elevated blood pressure readings. Conventionally, this diagnosis was based on three separate sphygmomanometer recordings taken at monthly intervals. During the initial evaluation, a thorough medical history and complete physical examination are essential. With the introduction of 24-hour ambulatory monitoring devices and home blood pressure measuring equipment, greater emphasis is now placed on avoiding misdiagnosis in individuals who only exhibit high readings in a clinical environment (white coat hypertension). As a result, guidelines have been updated. In the United Kingdom, a single elevated blood pressure reading in a clinic is now followed by ambulatory blood pressure monitoring, or when not possible, by home monitoring for a period of one week.

5.1 Blood Pressure Measurements

Diagnosis is based on persistently elevated blood pressure measured with a validated device According to major guidelines (ACC/AHA).

Category	Systolic (mmHg)	Diastolic (mmHg)
1. Normal	<120	<80
2. Elevated	120–129	<80
3. Stage 1 Hypertension	130–139	80–89
4. Stage 2 Hypertension	≥140	≥90

Hypertension is diagnosed only after

At least two elevated readings, On two or more separate visits or confirmed by home BP monitoring (HBPM) or ambulatory BP monitoring (ABPM)

5.2 Preferred Methods for Confirmation

Ambulatory Blood Pressure Monitoring (ABPM) most accurate method hypertension is confirmed if

24-hour average $\geq 130/80$

Daytime average $\geq 135/85$

Nighttime average $\geq 120/70$

Home Blood Pressure Monitoring (HBPM) Hypertension is confirmed if: Average $\geq 135/8$

5.3 Evaluation After Diagnosis

If high BP is confirmed, clinicians typically assess

Medical history & medications

Physical exam

Labs (kidney function, electrolytes, glucose, lipids)

ECG

Screening for secondary causes (kidney disease, endocrine disorders, etc.)

5.4 Symptoms

Hypertension is often asymptomatic, but severe hypertension can cause:

Headache

Vision changes

Chest pain

Shortness of breath

Confusion

6. TREATMENT/MANAGEMENT

The management of hypertension subdivides into pharmacological and nonpharmacology management.

Non-pharmacological and lifestyle management are recommended for all individuals with raised BPs regardless of age, gender, comorbidities, or cardiovascular risk status.

Patient education is paramount to effective management and should always include detailed instructions regarding weight management, salt restriction, smoking management, adequate management of obstructive sleep apnea, and exercise. Patients need to be informed and revised at every encounter that these changes are to be continued lifelong for effective disease treatment.

Weight reduction is advisable if obesity is present, although optimum BMI and optimal weight range are still unknown. Weight reduction alone can result in decreases of up to 5 to 20 mm Hg in systolic blood pressure.

Smoking may not have a direct effect on blood pressure but will help in reducing long-term sequelae if the patient quits smoking

Lifestyle changes alone can account for up to a 15% reduction in all cardiovascular-related events.

Pharmacological therapy consists of angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), diuretics (usually thiazides), calcium channel blockers (CCBs), and beta-blockers (BBs), which are instituted taking into account age, race and comorbidities such as the presence of renal dysfunction, LV dysfunction, heart failure, and cerebrovascular disease. JNC-8, ACC, and ESC/ESH have their separate recommendations for pharmacological management

JNC-8 recommends the following

Starting pharmacological therapy for individuals with DM and CKD with BP greater than or equal to 140/90 mm Hg to therapeutic target BP less than 140/90 mm Hg.

Starting pharmacological therapy for individuals 60 years of age and over with BP greater than or equal to 150/90 mm Hg to therapeutic target BP less than 150/90 mm Hg.

Starting pharmacological therapy for individuals 18 to 59 years of age with SBP greater than or equal to 140 mm Hg to therapeutic target SBP less than 140 mm Hg.

Individuals with DM and non-black population, treatment should include a thiazide diuretic, CCB, and an ACEi/ARB.

Individuals in the black population, including those with DM, treatment should include a thiazide diuretic and CCB.

Individuals with CKD, treatment should be started with or include ACEi/ARB, and this applies to all CKD patients irrespective of race or DM status.

Specific drugs can be used by individuals to treat hypertension. Doctors frequently advise starting with a low dose. Typically, antihypertensive medicines only cause modest adverse effects. In order to control their blood pressure, patients with hypertension will eventually need to mix two or more medications.

Medications for hypertension include

Diuretics, including thiazides, chlorthalidone and indapamide

Beta-blockers and alpha-blockers

Calcium-channel blockers

Central agonists

Peripheral adrenergic inhibitor

Vasodilators

Angiotensin-converting enzyme (ACE) inhibitors

Angiotensin receptor blockers

6.1 Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers

Other antihypertensive medications targeting RAAS, such as direct renin inhibitors and mineralocorticoid receptor antagonists, are typically considered reserve medications because there is less clinical trial evidence supporting their use as first line antihypertensive therapy. Among medications that inhibit components of the RAAS, ACE inhibitors and angiotensin II receptor blockers are considered first line antihypertensives. In substantial trials for hypertension, ACE inhibitors and angiotensin II receptor blockers have been evaluated. Both medication classes improved outcomes in patients with heart failure with decreased left ventricular ejection fraction or with diabetic nephropathy, making them particularly advantageous in these populations. Both groups seem to be equally effective at lowering the risk of CVD.

6.2 Dihydropyridine calcium channel blockers

Dihydropyridine calcium channel blockers cause vasodilation by obstructing L-type calcium channels in vascular smooth muscle. They are potent antihypertensive medications with a wealth of knowledge from many clinical studies. This pharmacological class's ability to be taken with all other first-line antihypertensives is a practical benefit. A typical adverse effect, especially in obese people, is peripheral edema, which is explained by peripheral arterial vasodilation rather than worsening heart failure or renal disease. Nondihydropyridine calcium

channel blockers, especially verapamil, also lower cardiac calcium channels, which can reduce heart rate and cardiac contractility.^[1]

6.3 Thiazide-type and thiazide-like diuretic

Thiazide-type diuretic such as hydrochlorothiazide, lack the benzothiadiazine ring but thiazide-like diuretics, such as chlorthalidone, metolazone, and indapamide, do. Since the earliest trials demonstrating the morbidity advantages of antihypertensive medication, both subclasses of thiazide diuretics block Na⁺ and Clcotransporters in renal tubules, hence inducing natriuresis, and have been a crucial part of pharmacological hypertension control.

To achieve improved risk-benefit profiles, diuretic doses have been significantly decreased over time. However, whether or not this metabolic activity translates into long-term increases in CVD risk has been questioned. Thiazide-type and thiazide-like diuretics can affect glucose metabolism raising the risk for new onset diabetes mellitus.

6.4 Beta-adrenoreceptor blockers

By reducing cardiac output, heart rate, renin release, and effects on the adrenergic control of the nervous system, beta-adrenoreceptor blockers lower blood pressure. Betaadrenoreceptor blockers perform better than other first-line antihypertensives in reducing CVD morbidity and mortality after acute myocardial infarction and in patients with heart failure who have reduced left ventricular ejection fraction, but not when these comorbidities are present. This impact has been linked to decreased aortic BP decreases and negative effects of Beta-adrenoreceptor blockage on body weight and glucose metabolism.

With more recent beta-adrenoreceptor blockers, such as sinus node rate or atrioventricular conduction, some of these drawbacks may be decreased

6.5 MANAGEMENT

Reducing Salt

Intake of the average daily salt intake for people in the majority of nations is between 9 and 12 grammes(g). To reduce the risk of hypertension and related health issues, the World Health Organisation (WHO) advises lowering intake to under 5g a day.

- Instead, experts recommend
- A variety of fruit and vegetables
- Beans, pulses, and nuts

- Fish rich in omega-3 twice a week
- Nontropical vegetable oils, for example, olive
- Oil skinless poultry and fish
- Low fat dairy product
- Whole grain, high fiber food.

Managing Body Weight

Extra body weight might make hypertension worse. Losing weight typically causes blood pressure to drop since the heart doesn't have to work as hard to pump blood throughout the body.

Stress reduction

Avoiding or learning to manage stress can help a person control blood pressure. Meditation, warm baths, yoga, and simply going on long walks are relaxation techniques that can help relieve stress. People should avoid consuming alcohol, recreational drugs, tobacco, and junk food to cope with stress, as these can contribute to elevated blood pressure and the complications of hypertension. Smoking can increase blood pressure. Avoiding or quitting smoking reduces the risk of hypertension, serious heart conditions, and other health issues.

Regular physical exercise

Current guidelines recommend that all people, including those with hypertension, engage in at least 150 minutes of moderate intensity, aerobic exercise every week, or 75 minutes a week of high intensity exercises.

7. New developments in hypertension treatment in recent years

There have been several new developments in hypertension (high blood pressure) treatment in recent years, focusing on improving efficacy, targeting different mechanisms, and enhancing patient adherence. While many existing classes of antihypertensive drugs remain cornerstone treatments (eg, ACE inhibitors, calcium channel blockers, diuretics), newer drugs and approaches are expanding the options available. Here are some of the most notable recent innovations

7.1 Angiotensin Receptor-Nepriylsin Inhibitors (ARNIS)

Examples: Sacubitril/valsartan (Entresto)

Mechanism: This combination drug inhibits both the angiotensin II receptor (through valsartan) and neprilysin, an enzyme that breaks down natriuretic peptides (eg., BNP). Natriuretic peptides help dilate blood vessels and reduce blood pressure.

Recent Use: While primarily used for heart failure, it has also been found to be effective in managing hypertension, especially in patients with concurrent heart failure or chronic kidney disease.

7.2 Mineralocorticoid Receptor Antagonists (MRAS)

Examples: Finerenone (Kerendia)

Mechanism: MRAs block the action of aldosterone, which reduces sodium retention, lowers blood pressure, and provides additional kidney protection

Recent Use: Finerenone was recently approved for managing hypertension in patients with chronic kidney disease and type 2 diabetes. It has been shown to have a positive impact on cardiovascular outcomes and kidney function, offering a dual benefit for hypertension and kidney disease management.

7.3 New Calcium Channel Blockers (CCBs)

Examples: Amlodipine (for once-daily use), Clevidipine (IV formulation)

Mechanism: Calcium channel blockers (CCBs) relax blood vessels and decrease the heart's workload by blocking calcium entry into smooth muscle and heart cells.

Recent Development: Newer CCBs like Clevidipine are designed for IV use and offer quicker control over severe hypertension, especially in hospitalized patients. Oral formulations like Amlodipine remain popular, but new research focuses on improving side effects and patient adherence.

7.4 Sodium-Hydrogen Exchanger 1 (NHE1) Inhibitors

Example: Serelaxin (still under investigation)

Mechanism: NHE1 inhibitors work by interfering with sodium and proton exchange in cells, ultimately reducing the strain on the heart and blood vessels.

Recent Use: While NHEI inhibitors have primarily been explored for heart failure, they hold promise in treating hypertension by improving endothelial function and reducing vascular

resistance. More clinical studies are needed to solidify their role in hypertension management.

7.5 Rho Kinase Inhibitors

Examples: Fasudil (though not yet FDA-approved in the U.S.)

Mechanism: Rho kinase inhibitors work by interfering with the contractile mechanisms in smooth muscle cells, leading to vasodilation and reduced vascular resistance

Recent Development: While primarily used in Japan, these drugs are being explored for their potential to treat hypertension by promoting more flexible blood vessels and reducing pressure in the arterial walls. They are still undergoing clinical trials in Western countries.

7.6 Targeting the Endocannabinoid System

Mechanism: Some recent studies have shown that the endocannabinoid system (ECS) plays a role in regulating blood pressure. Newer research is looking at CB1 receptor antagonists or inverse agonists, which could potentially lower blood pressure by modulating vascular tone.

Status: While still experimental, drugs targeting the ECS might become a viable option for hypertension in the future.

7.7 Dual-Action Beta-Blockers

Example: Nebivolol (Bystolic)

Mechanism: Nebivolol is a beta-blocker with a unique mechanism: it not only blocks beta receptors to slow the heart rate but also increases nitric oxide production, leading to vasodilation

Recent Use: This drug has become popular in treating hypertension with fewer side effects (eg, reduced fatigue, less sexual dysfunction) compared to older beta-blockers like atenolol.

7.8 Fixed-Dose Combinations

Examples: Losartan/Hydrochlorothiazide (Hyzaar), Amlodipine/Olmesartan (Azor)

Mechanism: Combining drugs that act on different pathways (eg, an ACE inhibitor and a diuretic) allows for better blood pressure control while reducing pill burden for patients.

Recent Development: There's an increasing trend toward fixed-dose combinations for better patient adherence and convenience. These combos may involve combinations of ARBs (angiotensin receptor blockers), calcium channel blockers, and diuretics.

7.9 Selective SGLT2 Inhibitors

Examples: Empagliflozin (Jardiance), Canagliflozin (Invokana)

Mechanism: These drugs inhibit the sodium-glucose cotransporter 2 (SGLT2), reducing blood glucose levels and promoting diuresis, which can lower blood pressure.

Recent Use: SGLT2 inhibitors are primarily used in type 2 diabetes, but emerging data shows their potential in lowering blood pressure, especially in people with hypertension and diabetic kidney disease.

Future Directions

Research into more personalized hypertension treatments, including genetic factors influencing how patients respond to different drugs, is underway. Advances in nanotechnology and gene editing may eventually offer more targeted therapies.

Many of these drugs and therapies are still in the approval process or undergoing clinical trials, so their use may become more widespread in the coming years.

8. Complications of Hypertension

The following complications have been reported with uncontrolled hypertension in multiple large-scale population trials.

Coronary heart disease (CHD)

Myocardial infarction (MI)

Stroke (CVA), either ischemic or intracerebral hemorrhage

Hypertensive encephalopathy

Renal failure, acute versus chronic

Peripheral arterial disease

Atrial fibrillation

Aortic aneurysm

Death (usually due to coronary heart disease, vascular disease, or stroke-related)

9. CONCLUSION

Hypertension is a significant global health concern, and its prevalence is increasing due to the aging population. Preventive strategies, such as maintaining a healthy diet and engaging in regular physical activity, should be implemented early in life to reduce the risk of developing hypertension. For individuals already diagnosed, early detection and timely treatment are

essential to prevent complications. Effective management of hypertension often requires the use of combination therapy, as single medications may not provide adequate blood pressure control for many patients. Recent advances in hypertension therapy highlight a shift toward more targeted and patient-focused treatment strategies. While traditional drug classes such as ACE inhibitors, diuretics, and calcium channel blockers remain essential, newer options like ARNIs, selective MRAs, dual-action beta-blockers, and SGLT2 inhibitors offer additional benefits beyond blood pressure control, particularly in patients with heart failure, diabetes, and kidney disease. Experimental agents and innovative mechanisms such as Rho kinase inhibitors, NHEI inhibitors, and drugs acting on the endocannabinoid system show promising potential, though further clinical validation is required. The growing use of fixed-dose combinations also reflects an emphasis on improving patient adherence and long-term outcomes. Overall, emerging therapies indicate a future where hypertension management will be more personalized, effective, and supported by advanced pharmacological research.

10. REFERENCE

1. Whelton, P.K, et al. (2018) 2017. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines *Journal of the American College of Cardiology*, 71, e127-e248.
2. Muntner, P., et al. (2018) Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline *Circulation*; 137: 109118.
3. Lim, S.S., et al. (2012) A Comparative Risk Assessment of Burden of Disease and Injury Attributable to 67 Risk Factors and Risk Factor Clusters in 21 Regions, 1990-2010: A Systematic Analysis for the Global Burden Of Disease Study 2010. *Lancet*, 380: 2224-2260.
4. Lloyd-Jones, D., et al. (2009) Heart Disease and Stroke Statistics- 2009 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*, 119: 480486.
5. Aronow, W.S., et al. (2009) A Propensity-Matched Study of the Association of Peripheral Arterial Disease with Cardiovascular Outcomes in Community-Dwelling Older Adults. *American Journal of Cardiology*, 103: 130-135.

6. Aronow, W.S., et al. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Circulation*, 123: 2434-2506.
7. Persell, S.D. (2011) Prevalence of Resistant Hypertension in the United States, 2003-2008. *Hypertension*, 57: 1076-1080.
8. Calhoun, D.A., et al. (2014) Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population Based Cohort. *Hypertension*, 63: 451-458.
9. Tomaszewski, M., et al. (2014) High Rates of Non-Adherence to Antihypertensive Treatment Revealed by High-Performance Liquid Chromatography-Tandem Mass Spectrometry (HP LC-MS/MS) Urine Analysis. *Heart*, 100: 855-861.
10. England Public Health. Health matters: combating high blood pressure. Public Health England, 2017 Accessed March 2019.
11. Organisation WH. World Health Organization (2013), A global brief on hypertension. Report. 2013 April 2013. Contract No.: WHO/DCO/WHD/2013.2
12. Brinker, S., et al. (2014) Therapeutic Drug Monitoring Facilitates Blood Pressure Control in Resistant Hypertension. *Journal of the American College of Cardiology*, 63: 834-835.
13. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014; 129: S76-S99.
14. Tabrizi, J. S., Sadeghi-Bazargani, H, Farahbakhsh, M., Nikniaz, L., & Nikniaz, Z. (2016). Prevalence and associated factors of prehypertension and hypertension in Iranian population: The Lifestyle Promotion Project (LPP) *PLoS ONE*, 11(10): e0165264. <https://doi.org/10.1371/journal.pone.0165264>.
15. Mahmood, S, Levy, D., Vasan, R., & Wang, T. (2014). The Framingham Heart Study and the Epidemiology of cardiovascular disease: a historical perspective. *The Lancet*, 383: 999-1008. [https://doi.org/10.1016/S0140-6736\(13\)61752-3](https://doi.org/10.1016/S0140-6736(13)61752-3).
16. Mills, K., Stefanescu, A., & He, J (2020) The global epidemiology of hypertension. *Nature Reviews Nephrology*, 16: 223-237. <https://doi.org/10.1038/s41581-019-0244-2>
17. Sadeeqa, S. (2019). Hypertension: A Case Study. *Virology & Immunology Journal* <https://doi.org/10.23880/vij-16000211>.
18. Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A, Schlaich, M., Stergiou, G. S., Tomaszewski, M., Wainford, R D., Williams, B., & Schutte, A. E. (2020) 2020 International Society of Hypertension Global

- Hypertension Practice Guidelines. *Hypertension*, 75(6): 1334-1357. <https://doi.org/10.1161/hypertensionaha.120.15026>.
19. Omboni, S., Aristizabal, D., De La Sierra, A., Dolan, E., Head, G., Kahan, T., Kantola, I., Kario, K., Kawecka-Jaszcz, K., Malan, L., Narkiewicz, K., Octavio, J., Ohkubo, T., Palatini, P., Siegelová, J., Silva, E., Stergiou, G., Zhang, Y., Mancia, G., & Parati, G. (2016). Hypertension types defined by clinic and ambulatory blood pressure in 14143 patients referred to hypertension clinics worldwide. Data from the ARTEMIS study. *Journal of Hypertension*, 34: 2187-2198. <https://doi.org/10.1097/HJH.0000000000001074>.
 20. Little, P. (2002). Comparison of agreement between different measures of blood pressure in primary care and daytime ambulatory blood. *Pressure BMJ*, 325(7358), 254. <https://doi.org/10.1136/bmj.325.7358.254>.
 21. Guo, J., Lv, J., Guo, Y., Bian, Z., Zheng, B., Wu, M., Yang, L., Chen, Y., Su, J., Zhang, J., Yao, J., Chen, J., Chen, Z., Yu, C., & Li, L. (2021) Association between blood pressure categories and cardiovascular disease mortality in China. *PLoS ONE*, 16(7), e0255373 <https://doi.org/10.1371/journal.pone.0255373>.
 22. Stergiou, G. S., Kyriakoulis, K. G., & Kollias, A. (2018). Office blood pressure measurement types: Different methodology-Different clinical conclusions *Journal of Clinical Hypertension*, 20(12), 1683-1685. <https://doi.org/10.1111/jch.13420>.
 23. World Health Organization. (2019). Hypertension: Key Facts. WHO Report.
 24. GBD 2017 Risk Factor Collaborators (2018). Comparative risk assessment of 84 risk factors. *The Lancet*, 392(10159): 1923-1994.
 25. Chobanian, A. V., et al (2003). The Seventh Report on High Blood Pressure *JAMA*, 289(19), 2560-2572.
 26. Whelton, P K, et al (2018) 2017 ACC/AHA Hypertension Guidelines *Hypertension*, 71(6); e13-e115.
 27. Padmanabhan, S., et al. (2015). Genetic determinants of blood pressure. *Nature Reviews Cardiology*, 12(2): 52-66.
 28. Esler, M., et al. (2008). Sympathetic nervous system and hypertension. *Hypertension*, 52(4): 596-605.
 29. Appel, L. J., et al (1997). Effects of dietary patterns on blood pressure *New England Journal of Medicine*, 336(16): 1117-1124.
 30. Lackland, D. T, & Weber, M. A (2015) Global burden of cardiovascular disease *Journal of the American Society of Hypertension*, 9(3): 153-158.

31. Lavie, C. J, et al (2015) Impact of physical activity on hypertension Progress in Cardiovascular Diseases, 57(4): 401-406.
32. Mancia, G., et al. (2013). ESH/ESC guidelines on hypertension European Heart Journal, 34(28): 2159-2219.
33. Skorupskaite, K., et al (2020) Aerobic exercise and cardiovascular health Journal of Clinical Endocrinology & Metabolism, 105(5): 165-176.
34. Fuchs, F D., & Whelton, P. K (2020). Hypertension and cardiovascular risks. Circulation Research, 126(6): 830-846.
35. Cornelissen, V A., et al. (2013) Exercise training and blood pressure. Journal of Hypertension, 31(6): 1040-1051.
36. Yusuf, S., et al. (2004). Effect of modifiable risk factors on myocardial infarction in 52 countries. The Lancet, 364(9438): 937-952.
37. Appel, L. J., et al. (2011). Dietary patterns and blood pressure. Hypertension, 58(5): 793-800.